ScoreWhy is Apellis Pharmaceuticals, Inc. ?
1
With a growth in Operating Profit of 97.06%, the company declared Outstanding results in Sep 25
- OPERATING CASH FLOW(Y) Highest at USD 78.86 MM
- ROCE(HY) Highest at 14.1%
- RAW MATERIAL COST(Y) Fallen by -14.51% (YoY)
2
Rising Promoter Confidence
- Promoters have increased their stake in the company by 0.63% over the previous quarter and currently hold 5.83% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Apellis Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Apellis Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Apellis Pharmaceuticals, Inc.
-26.96%
-0.90
65.07%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
299.43%
EBIT Growth (5y)
16.85%
EBIT to Interest (avg)
-15.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.61
Sales to Capital Employed (avg)
0.94
Tax Ratio
0.60%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
54
Industry P/E
Price to Book Value
6.01
EV to EBIT
29.76
EV to EBITDA
29.16
EV to Capital Employed
6.26
EV to Sales
2.35
PEG Ratio
0.46
Dividend Yield
NA
ROCE (Latest)
21.03%
ROE (Latest)
11.21%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend37What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 78.86 MM
ROCE(HY)
Highest at 14.1%
RAW MATERIAL COST(Y)
Fallen by -14.51% (YoY
NET SALES(Q)
Highest at USD 458.58 MM
OPERATING PROFIT(Q)
Highest at USD 223.52 MM
OPERATING PROFIT MARGIN(Q)
Highest at 48.74 %
PRE-TAX PROFIT(Q)
Highest at USD 216.32 MM
NET PROFIT(Q)
Highest at USD 215.72 MM
EPS(Q)
Highest at USD 1.66
-1What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Apellis Pharmaceuticals, Inc.
Net Sales
At USD 458.58 MM has Grown at 132.98%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 216.32 MM has Grown at 480.48%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 215.72 MM has Grown at 475.52%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 78.86 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 458.58 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 223.52 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 48.74 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 216.32 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 215.72 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 1.66
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -14.51% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Apellis Pharmaceuticals, Inc.
Non Operating Income
Highest at USD 0.02 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
